SCHEMBL16158084

SCHEMBL16158084

CC(C)CCCC(C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](OC(=O)CCC(=O)NCCCOCCO)CC[C@]4(C)[C@H]3CC[C@]12C

nearest known ligand 0.71

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ POLA1 P09884 1/20 0.62
▸ CYP46A1 Q9Y6A2 2/20 0.60
▸ PLA2G2A P14555 1/20 0.59
▸ OSBP P22059 3/20 0.56
▸ USP2 O75604 2/20 0.56
▸ RORC P51449 2/20 0.56
▸ LMNA P02545 1/20 0.56
▸ ABCB1 P08183 1/20 0.56
▸ OSBP2 Q969R2 1/20 0.56
▸ NPC1 O15118 1/20 0.56
▸ GBA1 P04062 2/20 0.53
▸ UGCG Q16739 2/20 0.53
▸ GBA2 Q9HCG7 2/20 0.53
▸ NR1H3 Q13133 4/20 0.53
▸ GRIN1 Q05586 1/20 0.53
▸ GRIN2A Q12879 1/20 0.53
▸ NPC1L1 Q9UHC9 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24435883 0.94 PLA2G2A (0.62) POLA1CYP46A1PLA2G2AOSBPUSP2
SCHEMBL16174261 0.94 PLA2G2A (0.62) POLA1CYP46A1PLA2G2AOSBPUSP2
SCHEMBL16172138 0.94 PLA2G2A (0.62) POLA1CYP46A1PLA2G2AOSBPUSP2
SCHEMBL19115392 0.94 POLA1 (0.61) POLA1CYP46A1PLA2G2AOSBPUSP2
SCHEMBL23876215 0.94 POLA1 (0.68) POLA1CYP46A1PLA2G2AOSBPUSP2
SCHEMBL12325985 0.93 CYP46A1 (0.68) POLA1CYP46A1PLA2G2AOSBPUSP2
SCHEMBL20620339 0.92 POLA1 (0.62) POLA1CYP46A1PLA2G2AOSBPUSP2
SCHEMBL16158050 0.91 POLA1 (0.66) POLA1CYP46A1PLA2G2AOSBPUSP2
SCHEMBL27322570 0.91 POLA1 (0.66) POLA1CYP46A1PLA2G2AOSBPUSP2
SCHEMBL22503885 0.91 POLA1 (0.59) POLA1CYP46A1PLA2G2AOSBPUSP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10906867-B2 Lipids and lipid compositions for the delivery of active agents NOVARTIS AG (CH) 2021-02-02 — — US disclosed
US-9504747-B2 Lipids and lipid compositions for the delivery of active agents NOVARTIS AG (CH) 2016-11-29 — — US disclosed
US-20160311759-A1 Lipids and Lipid Compositions for the Delivery of Active Agents NOVARTIS AG (CH) 2016-10-27 — — US disclosed
US-20140303232-A1 LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS NOVARTIS AG (CH) 2014-10-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10906867-B2 Lipids and lipid compositions for the delivery of active agents LPAR1, LPAR4, LIPA POLA1 3246/4885CYP46A1 212/4885PLA2G2A 39/4885
US-20140303232-A1 LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS LIPA, LPAR1, LPAR4 POLA1 3763/4885CYP46A1 145/4885PLA2G2A 48/4885
US-20160311759-A1 Lipids and Lipid Compositions for the Delivery of Active Agents PHOSPHO1, SGMS1, ABCB4 POLA1 3801/4885CYP46A1 170/4885PLA2G2A 36/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback